Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 20;5(10):ofy242.
doi: 10.1093/ofid/ofy242. eCollection 2018 Oct.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

Sharon A Riddler  1 , Lu Zheng  2 , Christine M Durand  3 , Justin Ritz  2 , Richard A Koup  4 , Julie Ledgerwood  4 , Robert T Bailer  4 , Susan L Koletar  5 , Joseph J Eron  6 , Michael C Keefer  7 , Bernard J C Macatangay  1 , Joshua C Cyktor  1 , John W Mellors  1 ; AIDS Clinical Trials Group A5342 Protocol Team
Collaborators, Affiliations

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

Sharon A Riddler et al. Open Forum Infect Dis. .

Abstract

Background: Broadly neutralizing monoclonal antibodies (bnMAbs) may promote clearance of HIV-1-expressing cells through antibody-dependent cell-mediated cytotoxicity. We evaluated the effect of the CD4-binding site bnMAb, VRC01, on measures of HIV-1 persistence in chronically infected individuals.

Methods: A5342 was a phase 1, randomized, double-blind, placebo-controlled, parallel-arm study. Participants on effective antiretroviral therapy (ART) were randomized to receive 2 infusions of VRC01 (40 mg/kg) at entry and week 3, and 2 infusions of placebo (saline) at weeks 6 and 9; or 2 infusions of placebo at entry and week 3, and 2 infusions of VRC01 at weeks 6 and 9.

Results: Infusion of VRC01 was safe and well tolerated. The median fold-change in the cell-associated HIV-1 RNA/DNA ratio from baseline to week 6 was 1.12 and 0.83 for the VRC01 and placebo arms, respectively, with no significant difference between arms (P = .16). There were no significant differences in the proportions with residual plasma viremia ≥1 copies/mL or in phorbol 12-myristate 13-acetate/ionomycin-induced virus production from CD4+ T cells between arms (both P > .05).

Conclusions: In individuals with chronic HIV-1 infection on ART, VRC01 infusions were safe and well tolerated but did not affect plasma viremia, cellular HIV-1 RNA/DNA levels, or stimulated virus production from CD4+ T cells.

Clinicaltrialsgov identifier: NCT02411539.

Keywords: HIV-1 cure; HIV-1 persistence; VRC01; bnMAb; clinical trial.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study design.
Figure 2.
Figure 2.
Consolidated Standards of Reporting Trials (CONSORT) diagram.
See this image and copyright information in PMC

References

    1. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999; 96:10958–61. - PMC - PubMed
    1. Finzi D, Blankson J, Siliciano JD, et al. . Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512–7. - PubMed
    1. Besson GJ, Lalama CM, Bosch RJ, et al. . HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 2014; 59:1312–21. - PMC - PubMed
    1. Ferrari G, Pollara J, Kozink D, et al. . An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029–36. - PMC - PubMed
    1. Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. Immunol Rev 2017; 275:313–23. - PMC - PubMed

Associated data